908 Devices Inc. Stock Price, News & Analysis

908 Devices (NASDAQ: MASS) announced that the Romanian Customs Authority has successfully deployed 27 MX908 devices across its border operations for enhanced security measures. The handheld mass spectrometers, delivered earlier this year, enable real-time identification of trace chemicals, particularly drugs and explosives. The devices can detect trace levels of substances on vehicles, containers, and packages within seconds, allowing customs officials to make quick, informed decisions during inspections.

The order was secured through 908 Devices' channel partner, MATE-FIN, via an EU Customs Control Equipment Instrument program. The deployment and training were completed in early 2025, strengthening Romania's border security capabilities and its contribution to European Community safety.

908 Devices (NASDAQ: MASS) reported strong Q1 2025 financial results with total revenue reaching $11.8 million, up 59% year-over-year. The company's handheld product and service revenue grew 86% to $11.0 million. Recurring revenue increased 54% to $4.4 million, representing 37% of total revenues. The installed base expanded 28% to 3,172 devices. Despite revenue growth, the company reported a net loss from continuing operations of $9.8 million. Notable achievements include a $2.0 million order from Texas Department of Public Safety and shipment of over 25 MX908 devices for Ukraine. The company divested its bioprocessing portfolio to Repligen, resulting in a net gain of $56.6 million. 908 Devices maintains its 2025 revenue guidance of $53-55 million, projecting 11-15% growth. Cash position stands strong at $124.3 million with no debt.

908 Devices has secured significant contracts to supply advanced chemical detection devices to the European Union's rescEU disaster preparedness initiative. The company has delivered 108 devices to EU member states over the past six months.

Key deployments include:

• Czech Fire Brigade: 6 MX908 mass spectrometry devices for Q2 2025, adding to their existing 12 devices (XplorIR and ThreatID)
• Finland: 90 ProtectIR handheld FTIR analyzers, delivered across Q4 2024 and Q1 2025

These devices enhance disaster response capabilities by enabling rapid identification of chemical, biological, radiation, and nuclear (CBRN) threats. The MX908 can detect hazardous substances in multiple forms, while ProtectIR can identify over 23,000 chemical substances.

908 Devices (Nasdaq: MASS) has received a $2 million order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This follows an initial order from last year and is funded through the Community Oriented Policing Services (COPS) grant.

The MX908 devices, shipped in April, will be deployed throughout Texas at critical interdiction locations. The technology enables first responders to detect and identify trace amounts of hazardous substances, including synthetic opioids like fentanyl and nitazenes, and counterfeit pills.

The investment comes amid rising fentanyl-related deaths in Texas, which have increased by 158% from 2020 to 2023. The devices will support agencies including the Criminal Investigations Division and Narcotics Enforcement in modernizing frontline detection capabilities to combat the opioid crisis.

908 Devices (Nasdaq: MASS) reported preliminary Q1 2025 financial results, showing strong revenue growth of 55% from continuing operations, reaching at least $11.5 million compared to $7.4 million in Q1 2024. The company recently divested its desktop portfolio, generating an additional $1.1 million in revenue that will be reported under discontinued operations.

The company maintains a strong financial position with approximately $124 million in cash, cash equivalents, and marketable securities, plus $4.0 million held in escrow from the desktop portfolio divestiture. Following this strategic move, 908 Devices is focusing on its advanced chemical detection strategy, with management reaffirming their commitment to achieving Adjusted EBITDA positivity by Q4 2025.

908 Devices (Nasdaq: MASS) has secured a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module, scheduled for priority shipment in Q1 2025.

The MX908 devices, featuring proprietary High Pressure Mass Spectrometry (HPMS) technology, will be integrated into environmental testing kits for post-war applications. The system is designed to detect and identify trace levels of hazardous materials, including explosives, chemical agents, and priority drugs.

The Aero module enhancement enables rapid detection of aerosolized threats, including chemical warfare agents, pharmaceutical-based agents, and opioid analogs, providing first responders with critical actionable information for public safety.

908 Devices (NASDAQ: MASS) announced a strategic transformation and Q4/FY2024 financial results. The company divested its desktop portfolio to Repligen for $70 million, strengthening its focus on handheld chemical analysis devices.

Key financial highlights include:

• Q4 2024 revenue: $18.8M (+31% YoY)
• Full year 2024 revenue: $59.6M (+19% YoY)
• Handheld revenue: $46.1M (+22% YoY)
• Recurring revenue: $23.3M (39% of total revenue)

The company expects 11-15% revenue growth in 2025, with anticipated acceleration above 20% in 2026. The transformation reduces headcount by 33%, eliminates $20M in annual operating losses, and aims to achieve Adjusted EBITDA positivity by Q4 2025 and cash flow positivity in 2026. Gross margins are projected to reach mid-to-high 50% range in 2025.

Repligen (RGEN) has acquired the desktop bioprocessing analytics portfolio from 908 Devices (MASS) for $70 million in cash. The acquisition includes four PAT (Process Analytical Technology) devices: MAVERICK, MAVEN, REBEL, and ZipChip.

The acquired technologies enable real-time monitoring, control of bioprocess parameters, cell culture media analysis, and high-resolution sample separations for product quality characterization. This strategic move strengthens Repligen's PAT portfolio and expands its capabilities across the entire bioprocess workflow.

Following the transaction, 908 Devices will focus on growing its handheld device portfolio for health and safety applications. The deal includes the transfer of 908's bioprocessing team to Repligen.

908 Devices (Nasdaq: MASS), a pioneer in handheld and desktop chemical analysis devices, has announced its participation in two major investor conferences. The company will be featured in:

• A fireside chat at the TD Cowen 45th Annual Healthcare Conference in Boston on March 5 at 9:50 a.m. Eastern Time
• A fireside chat at the Leerink Global Healthcare Conference in Miami on March 11 at 1:00 p.m. Eastern Time

Investors and interested parties can access live and archived webcasts of both sessions through the company's investor relations website at www.908devices.com.